8-K: Aethlon Medical Reports Q4 FY2025 Results, Advances Hemopurifier Cancer Trial and Reduces Operating Expenses

Aethlon Medical announced its fiscal fourth-quarter 2025 financial results, highlighting progress in its Hemopurifier cancer trials in Australia and India, significant reductions in operating expenses, and advancements in its Long COVID research.

Summary

• Aethlon Medical reported financial results for its fiscal fourth quarter ended March 31, 2025.
• The company treated the first three patients in its Hemopurifier cancer trial at Australian sites, with all completing a single 4-hour treatment without device deficiencies or immediate complications.
• Indian regulatory approval was received on June 19, 2025, to initiate a similar oncology study at Medanta Medicity Hospital.
• The trial protocol for the cancer study was expanded to include patients receiving combination therapies with Pembrolizumab (Keytruda) or Nivolumab (Opdivo).
• Preclinical data published on May 12, 2025, showed the Hemopurifier removed 98.5% of platelet-derived extracellular vesicles (PD-EVs) in simulated treatment, supporting broader applications beyond cancer.
• A collaboration with UCSF on Long COVID research was accepted for a poster presentation at the Keystone Symposium (August 10-13, 2025).
• Operating expenses for fiscal year ended March 31, 2025, were approximately $9.3 million, a decrease of $3.3 million (26%) compared to $12.6 million in fiscal year ended March 31, 2024.
• The reduction in operating expenses was primarily due to lower payroll and related expenses ($1.3 million decrease), professional fees ($1.3 million decrease), and general and administrative costs ($660,000 decrease).
• Payroll reductions included a $900,000 decrease in salaries and an $800,000 decrease in stock-based compensation, partially offset by $400,000 in severance expenses.
• Professional fee savings included $600,000 in legal costs and $500,000 related to contract manufacturing and lab services.
• General and administrative reductions included $534,000 in raw material purchases and manufacturing facility costs, and $337,000 in laboratory supplies.
• These reductions were partially offset by a $467,000 increase in clinical trial expenses for the Australian oncology study.
• The operating loss decreased to $9.3 million for fiscal year 2025 from $12.6 million for fiscal year 2024.
• Cash balance as of March 31, 2025, was approximately $5.5 million.
• Other expenses for fiscal year 2025 included a non-cash charge of approximately $4.6 million related to a warrant inducement offer in March 2025.
• The company recognized approximately $324,450 in other income from the Employee Retention Tax Credit (ERTC) and $36,339 in interest income related to ERTC during fiscal 2025.
• Net loss attributable to common stockholders increased to $(13,388,090) for fiscal year 2025 from $(12,208,174) for fiscal year 2024.
• Basic and diluted net loss per share was $(8.58) for fiscal year 2025, compared to $(38.87) for fiscal year 2024.

Sentiment

Score: 6

Explanation: The document presents a mixed bag of positive clinical and operational progress alongside an increased net loss due to a non-cash charge. The reduction in operating expenses and clinical advancements are positive, but the increased net loss and the need for future capital raise temper overall sentiment.

Positives

• First three patients successfully treated in Hemopurifier cancer trial in Australia without device deficiencies or immediate complications, triggering DSMB review.
• Received Indian regulatory approval to initiate a similar oncology study, expanding global clinical reach.
• Trial protocol expanded to include combination therapies, aligning with evolving immunotherapy standards.
• Preclinical data demonstrated 98.5% removal of platelet-derived EVs, supporting broader applications beyond cancer, including Long COVID.
• Significant reduction in consolidated operating expenses by $3.3 million (26%) to $9.3 million for fiscal year 2025.
• Operating loss decreased to $9.3 million for fiscal year 2025 from $12.6 million for fiscal year 2024.
• Cash balance remained stable at approximately $5.5 million as of March 31, 2025.
• Recognition of $324,450 in Employee Retention Tax Credit (ERTC) and $36,339 in related interest income.
• Net loss per share significantly improved to $(8.58) from $(38.87) due to increased weighted average shares outstanding.

Negatives

• Net loss attributable to common stockholders increased to $(13,388,090) for fiscal year 2025 from $(12,208,174) for fiscal year 2024.
• Incurred a significant non-cash charge of approximately $4.6 million related to a warrant inducement offer in March 2025.
• Increased clinical trial expenses by $467,000 associated with the ongoing oncology study in Australia.
• Cash balance of $5.5 million may be insufficient for long-term operations given ongoing clinical trials and R&D.

Risks

• Ability to raise additional capital on terms favorable to the Company, or at all.
• Ability to successfully complete development of the Hemopurifier.
• Ability to successfully demonstrate the utility and safety of the Hemopurifier in cancer and infectious diseases and in the transplant setting.
• Ability to achieve and realize the anticipated benefits from potential milestones.
• Ability to obtain approval from the Ethics Committee of its third location in Australia, including on the timeline expected by the Company.
• Ability to enroll additional patients in its oncology clinical trials in Australia and India, including on the timeline expected by the Company.
• Ability to manage and successfully complete its clinical trials.
• Ability to successfully manufacture the Hemopurifier in sufficient quantities for its clinical trials.
• Unforeseen changes in regulatory requirements.
• Risks associated with the Company's collaborative research with UCSF Long COVID Clinic.
• Ability to further research potential applications of the Hemopurifier in other EV-associated diseases and other potential risks.

Future Outlook

The company expects preliminary data from the first cohort of the Australian cancer trial, including effects on extracellular vesicle (EV) removal and anti-tumor T-cell activity, in approximately three months. These findings are intended to guide the design of future safety and efficacy trials, including a potential Premarket Approval (PMA) study. The company also plans to begin the Indian trial following a Site Initiation Visit (SIV). Research into potential applications of the Hemopurifier in other EV-associated diseases, such as Long COVID, is ongoing, with findings to be presented at the Keystone Symposium in August 2025.

Management Comments

• Aethlon streamlined operations and significantly reduced its operating expenses, positioning the company for sustained focus on its clinical and regulatory goals.

Industry Context

Aethlon Medical operates in the medical therapeutic space, specifically developing devices for cancer and infectious diseases. The expansion of its cancer trial protocol to include combination therapies with Pembrolizumab (Keytruda) or Nivolumab (Opdivo) reflects the evolving standard of care in oncology, where combination immunotherapies are becoming more prevalent. The focus on extracellular vesicles (EVs) and their role in cancer progression and resistance to anti-PD-1 therapies positions Aethlon within the growing field of EV-based diagnostics and therapeutics. The company's research into Long COVID also addresses a significant unmet medical need, with an estimated 44-48 million affected individuals in the U.S. and a substantial economic burden, aligning with broader public health concerns and research efforts.

Comparison to Industry Standards

• The company's Hemopurifier is designed to improve therapeutic response rates to anti-PD-1 antibodies like Pembrolizumab (Keytruda) and Nivolumab (Opdivo). Currently, only about 30% of patients receiving these standard-of-care therapies experience lasting clinical responses, indicating a significant unmet need that Aethlon aims to address.
• The preclinical data showing 98.5% removal of platelet-derived EVs is a strong indicator of the device's potential efficacy in a field where EV removal is a novel therapeutic approach.
• The FDA Breakthrough Device designation for the Hemopurifier in advanced/metastatic cancer and life-threatening viruses suggests recognition of its potential to provide more effective treatment for serious conditions compared to existing options.
• The company's focus on Long COVID, affecting 44-48 million people in the U.S. with an estimated $2 billion economic burden, highlights its engagement with a major public health challenge, aligning with global research and development efforts in this area.

Management Changes

Corporate Governance

Related Party Transactions

• Due to related parties: $579,565 as of March 31, 2025, compared to $546,434 as of March 31, 2024.

Stakeholder Impact

• Shareholders: Impacted by the increased net loss due to the warrant inducement offer, but also by the progress in clinical trials and reduced operating expenses which could improve long-term value. The warrant inducement offer diluted existing shareholders by issuing new warrants.
• Employees: Affected by workforce reductions in August 2024 and executive terminations, leading to reduced payroll expenses but also severance costs.
• Patients: Potential beneficiaries of the Hemopurifier's development for cancer and Long COVID, offering new treatment options for unmet medical needs.
• Creditors: The company's cash balance and reduced operating expenses may provide some stability, but the ongoing net losses and potential need for capital raise could be a concern.
• Suppliers/Contractors: Impacted by reduced reliance on outside services for manufacturing facility maintenance and termination of services with a contract manufacturing organization.

Next Steps

• First meeting of an independent Data Safety Monitoring Board (DSMB) to review safety data from the first cohort of the Australian cancer trial and recommend advancement to the second treatment cohort.
• Preliminary data from the first cohort of the Australian cancer trial (EV removal and anti-tumor T-cell activity) expected in approximately three months.
• Initiation of the Indian oncology trial following a Site Initiation Visit (SIV) by Aethlon's India-based CRO, Qualtran.
• Manuscript describing the preclinical study results submitted to a peer-reviewed journal for publication.
• Poster presentation of collaborative research with UCSF Long COVID Clinic at the Keystone Symposium (August 10-13, 2025).
• Design of future safety and efficacy trials, including a potential Premarket Approval (PMA) study, guided by current study findings.

Key Dates

Recommendation

Keywords

Aethlon Medical, Hemopurifier, cancer trial, oncology, infectious diseases, Long COVID, extracellular vesicles, EVs, anti-PD-1 therapy, immunotherapy, clinical trial, medical device, FDA Breakthrough Device, financial results, operating expenses, Nasdaq: AEMD, CDSCO, India regulatory approval, Australia clinical trial